Oct 30, 2026, 09:01 UTC
GENMAB A/S shares rose during a breakout week, adding about $10 billion in market value, amid stellar cancer-drug data.
Source:Oct 28, 2026, 17:21 UTC
GENMAB A/S shares surged to a record high.
Source:Oct 28, 2026, 13:40 UTC
GENMAB A/S announced positive topline results from the Phase 3 LiGeR-HN1 trial, reporting that petosemtamab plus pembrolizumab met both primary endpoints and reduced the risk of death by 50% versus pembrolizumab alone in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma.
Source:Oct 26, 2026, 15:08 UTC
GENMAB A/S secured a clinical oncology partnership with Incyte.
Source:Oct 26, 2026, 11:00 UTC
GENMAB A/S announced updated Phase 2 trial results for petosemtamab plus pembrolizumab in first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma, reporting median overall survival of 28.2 months, an overall response rate of 63%, median progression-free survival of 9.0 months and a complete response rate of 19% among 43 efficacy-evaluable patients.
Source:Oct 26, 2026, 10:01 UTC
GENMAB A/S shares surged the most in more than six years after its experimental ovarian cancer treatment exceeded analyst expectations in a late-stage trial.
Source:Oct 25, 2026, 11:00 UTC
GENMAB A/S announced updated follow-up analyses from a Phase 2 study of petosemtamab with FOLFOX or FOLFIRI in metastatic colorectal cancer, reporting objective response rates of 75% in first-line patients, 67% in second-line patients, and 81% among first-line patients with left-sided tumors.
Source:Oct 24, 2026, 11:00 UTC
INCYTE CORP and GENMAB A/S announced a clinical trial collaboration in metastatic colorectal cancer.
Oct 23, 2026, 15:55 UTC
GENMAB A/S announced positive topline results from the Phase 3 RAINFOL-02 trial, reporting statistically significant and clinically meaningful improvements in progression-free survival and overall survival with rinatabart sesutecan versus GENMAB A/S in patients with platinum-resistant ovarian cancer.
Source:Oct 13, 2026, 10:22 UTC
GENMAB A/S announced that worldwide third-quarter 2026 net trade sales of DARZALEX, as reported by JOHNSON & JOHNSON, were USD 4,239 million, including USD 2,528 million in the United States and USD 1,711 million in the rest of the world.
Source:Oct 6, 2026, 09:51 UTC
Genmab (GMAB) shares jumped 10.7% in the previous trading session on above-average trading volume.
Source:Oct 6, 2026, 08:35 UTC
Genmab reported positive study results showing its Epkinly drug extended survival time for patients with a common type of lymphoma.
Source:Oct 5, 2026, 18:49 UTC
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial showing epcoritamab in combination with R-CHOP achieved statistically significant improvement in progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients, and will engage global regulatory authorities.
Oct 5, 2026, 14:00 UTC
Genmab shares continued to rise in Copenhagen, gaining as much as 6%.
Source:Sep 24, 2026, 18:32 UTC
Genmab A/S granted 13,794 restricted stock units and 13,331 warrants to employees of the company and its subsidiaries.
Source:Sep 8, 2026, 18:44 UTC
Genmab A/S increased its share capital by 28,011 shares due to the exercise of employee warrants, without preemption rights for existing shareholders.
Source:Aug 6, 2026, 18:04 UTC
Genmab announced two new Phase III studies of petosemtamab in colorectal cancer.
Source:Jun 30, 2026, 09:35 UTC
Genmab and AbbVie announced that their drug combination for lymphoma met the primary goal in a late-stage clinical trial.